Collaborative Arrangements and Acquisitions (Tables)

9 Months Ended

Sep. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of net income attributable to noncontrolling interest

An aggregate summary of net income attributable to noncontrolling interest related to the Company’s VIEs for the three and nine months ended September 30, 2018 and 2017 is as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
	(in thousands)
Loss attributable to noncontrolling interest before provision for (benefit from) income taxes and changes in fair value of contingent payments	$	411		$	238,946		$	1,394		$	222,448
Provision for (benefit from) income taxes	79			(120,181		)	6,068			(111,658		)
(Increase) decrease in fair value of contingent payments	(200		)	69,550			(23,100		)	62,560
Net loss (income) attributable to noncontrolling interest	$	290		$	188,315		$	(15,638	)	$	173,350

Summary of increase in fair value of contingent payments

During the three and nine months ended September 30, 2018 and 2017, the (increases) and decreases in the fair value of the contingent payments related to the Company’s VIEs were as follows:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2018			2017		2018			2017
	(in thousands)
Parion	$	—		$	69,550	$	—		$	63,460
BioAxone	(200		)	—		(23,100		)	(900		)

Schedule of collaborative arrangement summary of items related to variable interest entities

Significant amounts related to the Company’s consolidation of BioAxone as a VIE included in the Company’s condensed consolidated balance sheets as of the dates set forth in the table below were as follows:

	September 30, 2018		December 31, 2017
	(in thousands)
Restricted cash and cash equivalents (VIE)	$	8,143	$	1,489
Intangible assets	29,000		29,000
Deferred tax liability	9,414		4,756
Noncontrolling interest	28,365		13,727